Bag6 Antibody

What is BAG6 and what are its primary cellular functions?

BAG6 (also known as BAT3) is a multifunctional protein involved in several critical cellular processes. Primarily, BAG6 functions as a mediator of tail-anchored (TA) protein biogenesis and protein quality control . The protein contains a BAG-similar domain that is completely distinct from other canonical BAG domains, giving it unique functional properties . In humans, BAG6 forms a complex with Ubl4a, whereas its yeast homologue Get5 forms a homodimer .

BAG6 has been implicated in multiple cellular pathways including:

• Tail-anchored protein targeting to the endoplasmic reticulum

• Protein quality control and degradation of misfolded proteins

• Antiviral immune responses

• Tumor suppression activities

The protein's versatility stems from its ability to act as a scaffolding protein that simultaneously binds ubiquitylation machinery, the proteasome, TA-targeting factors, and proteins to be triaged .

How is BAG6 detected in different cellular compartments?

BAG6 can be detected in both nuclear and cytoplasmic compartments. Immunocytochemistry studies using BAG6 antibodies show specific staining localized to both nuclei and cytoplasm in immature human dendritic cells . The subcellular localization pattern can be visualized using fluorescent-conjugated secondary antibodies (such as NorthernLights™ 557-conjugated Anti-Sheep IgG) with DAPI counterstaining to highlight the nuclei .

For optimal detection, researchers typically use:

• Immersion fixation of cells

• BAG6-specific primary antibodies at 10 μg/mL concentration

• 3-hour incubation at room temperature

• Appropriate fluorophore-conjugated secondary antibodies

This dual localization reflects BAG6's involvement in both nuclear processes (such as gene regulation) and cytoplasmic functions (protein quality control, immune regulation).

How does BAG6 influence cancer progression in research models?

BAG6 demonstrates significant tumor-suppressing activity in pancreatic ductal adenocarcinoma (PDAC) models. Research using Bag6 knockout (Bag6 KO) tumor cells in mice shows that BAG6 deficiency results in significantly accelerated tumor growth compared to BAG6-expressing tumors .

Key findings from tumor model studies include:

• Bag6-deficient tumors grow much faster compared to Bag6-expressing tumors

• BAG6 deficiency leads to decreased T cell infiltration in the tumor microenvironment

• Bag6 KO tumors show accumulation of inflammatory cancer-associated fibroblasts (iCAFs)

• These changes create a tumor-promoting tumor microenvironment (TME)

• The growth-promoting effect of BAG6 deficiency is observed in both subcutaneous and orthotopic tumor models

• Notably, BAG6 knockout does not change tumor cell growth kinetics in vitro, suggesting the effect is mediated through TME modulation

These findings suggest BAG6 expression levels may serve as a prognostic indicator, with higher expression correlating with longer survival in pancreatic cancer patients .

What role does BAG6 play in viral infections?

BAG6 functions as a restriction factor against viral replication, particularly for influenza A virus (IAV). Research demonstrates that BAG6 inhibits IAV replication by targeting the viral polymerase subunit PB2 and disrupting the assembly of the viral RNA-dependent RNA polymerase (RdRp) complex .

Experimental evidence shows:

• Overexpression of BAG6 reduces viral protein expression and virus titers

• Deletion of BAG6 significantly enhances virus replication

• BAG6-knockdown mice develop more severe clinical symptoms and higher viral loads upon IAV infection

• BAG6 restricts viral transcription and replication by inhibiting viral RNA-dependent RNA polymerase activity

• The antiviral effect is observed against multiple influenza virus subtypes, including H1N1, H7N9, H9N2, and H5N1

Additionally, BAG6 negatively regulates RIG-I/VISA-mediated innate immune responses by targeting VISA. Overexpression of BAG6 inhibits Sendai virus (SeV)-induced activation of IFN-β, ISRE, and NF-κB in a dose-dependent manner, while reducing the transcription levels of IFNβ, ISG56, and CXCL10 .

What are the validated applications for BAG6 antibodies in research?

BAG6 antibodies have been validated for several experimental applications in research settings. The human/mouse/rat BAT3/BAG6 antibody has demonstrated efficacy in:

• Western Blot Analysis:

  • Detection of BAT3/BAG6 in multiple cell lines including A431 human epithelial carcinoma, HeLa human cervical epithelial carcinoma, BaF3 mouse pro-B cell, CH-1 mouse B cell lymphoma, and PC-12 rat adrenal pheochromocytoma

  • A specific band for BAT3/BAG6 is detected at approximately 150 kDa under reducing conditions

  • Recommended antibody concentration: 1 μg/mL

• Immunocytochemistry (ICC):

  • Detection of BAT3/BAG6 in immature human dendritic cells

  • Recommended antibody concentration: 10 μg/mL

  • Incubation: 3 hours at room temperature

  • Specific staining localizes to nuclei and cytoplasm

These validated applications make BAG6 antibodies valuable tools for studying the protein's expression, localization, and interactions in various experimental systems.

How should researchers optimize BAG6 antibody use for co-immunoprecipitation experiments?

For successful co-immunoprecipitation (co-IP) of BAG6 and its interacting partners, researchers should follow these methodological approaches:

• Cell Lysis Conditions:

  • For membrane protein interactions, use immunoprecipitation buffer containing:

    • 20 mM Tris-HCl, pH 7.5

    • 150 mM NaCl

    • 1 mM EDTA

    • 1% Nonidet P-40

    • Protease inhibitors (5 μg/ml leupeptin, 1 μg/ml pepstatin, 2 μg/ml aprotinin)

    • 1 mM dithiothreitol

• Alternative Lysis Buffer for Nuclear Proteins:

  • Radioimmune precipitation assay (RIPA) buffer containing:

    • 50 mM Tris-HCl, pH 7.5

    • 150 mM NaCl

    • 0.1% SDS

    • 0.5% sodium deoxycholate

    • 1% Nonidet P-40

• Affinity Purification:

  • For tagged BAG6, S-protein-agarose beads can be used (incubation for 2 hours at 4°C)

  • Wash beads four times with the appropriate lysis buffer

  • Elute bound materials with SDS sample buffer

• Detection:

  • Separate immunoprecipitated materials by SDS-PAGE

  • Transfer to nitrocellulose membranes

  • Immunoblot with specific antibodies against BAG6 and candidate interacting proteins

These protocols have been successfully employed to identify protein-protein interactions involving BAG6, including its association with Ubl4a and other co-chaperones.

How can researchers address variability in BAG6 detection across different species?

BAG6 is conserved across mammalian species, but there can be variability in detection efficacy when using antibodies across different species. To address this:

• Species Cross-Reactivity:

  • Select antibodies validated for cross-reactivity across relevant species

  • The Human/Mouse/Rat BAT3/BAG6 antibody has been validated to detect BAG6 in human, mouse, and rat samples, as demonstrated by successful detection in cell lines from all three species

• Optimization Strategies:

  • Determine optimal dilutions for each species through titration experiments

  • Adjust incubation times and temperatures based on signal strength

  • For Western blot applications, optimize protein loading amounts for different species

  • Consider alternative epitope-targeting antibodies if detection is consistently poor in specific species

• Epitope Conservation Analysis:

  • Compare the amino acid sequence of the BAG6 epitope across species

  • Select antibodies targeting highly conserved regions when multi-species detection is required

  • For the Human/Mouse/Rat BAT3/BAG6 antibody, the immunogen corresponds to amino acids Met1-Gln190 of human BAG6 (Accession # P46379)

This systematic approach will help ensure consistent and reliable BAG6 detection across experimental models involving different species.

What controls should be included when validating BAG6 antibody specificity?

Proper validation of BAG6 antibody specificity requires several critical controls:

• Positive Controls:

  • Include cell lines known to express BAG6 (e.g., A431, HeLa for human; BaF3, CH-1 for mouse; PC-12 for rat)

  • Recombinant BAG6 protein can serve as a positive control for Western blots

  • BAG6-overexpressing cells created through transfection

• Negative Controls:

  • BAG6 knockout or knockdown cells (CRISPR/Cas9-generated BAG6-deficient cell lines)

  • Secondary antibody-only controls to assess non-specific binding

  • Pre-absorption controls where antibody is pre-incubated with recombinant BAG6 protein

• Specificity Verification:

  • Molecular weight confirmation (BAG6 appears at approximately 150 kDa on Western blots under reducing conditions)

  • Peptide competition assays to confirm epitope specificity

  • Subcellular localization pattern (nuclear and cytoplasmic staining) consistent with known BAG6 distribution

• Reproducibility Assessment:

  • Consistent results across multiple experimental replicates

  • Consistent staining patterns in ICC/IF applications

  • Correlation between protein levels detected by Western blot and mRNA levels by qPCR

Implementing these validation controls ensures reliable interpretation of experimental data generated with BAG6 antibodies.

How can BAG6 antibodies be utilized to study protein quality control mechanisms?

BAG6 plays a crucial role in protein quality control pathways, making BAG6 antibodies valuable tools for studying these mechanisms:

• Tail-Anchored Protein Targeting Studies:

  • BAG6 antibodies can be used to immunoprecipitate the BAG6 complex (BAG6, TRC35, Ubl4A) to study its interaction with tail-anchored proteins

  • This complex serves as a crucial targeting factor for directing tail-anchored proteins to the ER membrane

  • The C-terminal domain of BAG6 bridges TRC35 and Ubl4A, creating a complex analogous to the Get4-5 heterotetramer found in yeast

• Protein Triage Investigations:

  • BAG6 antibodies can help track the fate of misfolded proteins

  • The proline-rich domain of BAG6 functions as a holdase domain binding to exposed hydrophobic regions and polyubiquitinated defective ribosomal products

  • Co-immunoprecipitation with BAG6 antibodies followed by mass spectrometry can identify novel substrates in the quality control pathway

• Ubiquitination Studies:

  • BAG6 antibodies can be used to study the role of BAG6 in connecting ubiquitination machinery with the proteasome

  • The N-terminal UBL domain of BAG6 interacts with the proteasome (RP non-ATPase 10c) and the ER (gp78 and ubiquitin regulatory X domain-containing protein 8)

  • These connections are central to BAG6's function in protein triage decisions

Understanding these mechanisms has implications for diseases involving protein misfolding and aggregation.

What methodological approaches can be used to study BAG6's role in immune regulation?

Recent research has identified BAG6 as an important regulator of immune responses, particularly in antiviral immunity. Methodological approaches to study this function include:

• RLR Signaling Pathway Analysis:

  • Use reporter assays with IFN-β promoter, ISRE, and NF-κB luciferase reporters to measure the impact of BAG6 on antiviral signaling

  • BAG6 overexpression inhibits Sendai virus-induced activation of these reporters in a dose-dependent manner

  • qPCR analysis to measure transcription levels of IFNβ, ISG56, and CXCL10 in BAG6-manipulated cells following viral infection

• Protein-Protein Interaction Studies:

  • Co-immunoprecipitation to study BAG6 interactions with components of the antiviral signaling pathway

  • BAG6 targets VISA in the RIG-I/VISA-mediated innate immune response

  • Western blot analysis to assess effects on IRF3 dimerization and phosphorylation of TBK1, P65, and IRF3

• BAG6 Knockout/Knockdown Models:

  • Generate BAG6-deficient cell lines using CRISPR/Cas9 gene editing

  • BAG6 deficiency enhances Sendai virus-mediated antiviral immune responses in human cell lines

  • In vivo virus challenge experiments in BAG6-knockdown mice to assess clinical symptoms and viral loads

• Viral Replication Assays:

  • Measure virus titers using TCID50 assays in BAG6-overexpressing or BAG6-depleted cells

  • BAG6 overexpression reduces viral protein expression and virus titers (10-15 fold lower)

  • Test multiple virus strains to determine the breadth of BAG6's antiviral activity

These methodologies enable detailed investigation of BAG6's role in immune regulation and antiviral defense mechanisms.

How might emerging technologies enhance BAG6 research using antibody-based approaches?

Several emerging technologies offer new opportunities for advancing BAG6 research:

• Proximity Labeling Techniques:

  • BioID or APEX2 fusions with BAG6 could identify transient or weak interactors in living cells

  • This approach would help map the complete BAG6 interactome across different cellular compartments

  • Particularly valuable for understanding BAG6's role in protein triage decisions and how it relates to other functions in apoptosis, gene regulation, and immunoregulation

• Super-Resolution Microscopy:

  • Techniques like STORM or PALM using fluorescently labeled BAG6 antibodies could reveal precise subcellular localization patterns

  • Could help resolve the spatial organization of BAG6 complexes during protein quality control or immune signaling events

  • May uncover previously unrecognized BAG6-enriched subcompartments

• Single-Cell Analysis:

  • Single-cell proteomics combined with BAG6 antibodies could reveal cell-to-cell variation in BAG6 expression and function

  • Particularly relevant for understanding BAG6's role in heterogeneous populations like immune cells or tumor microenvironments

  • Could help explain differential responses to viral infection or cancer progression

• CRISPR Screening:

  • Genome-wide CRISPR screens in combination with BAG6 antibody-based readouts could identify new regulators or pathways connected to BAG6 function

  • Validation of hits would require reliable BAG6 antibodies for protein analysis

These technological advances will likely provide deeper insights into BAG6's multifunctional nature and its role in diverse cellular processes.

What are the current knowledge gaps regarding BAG6 function that antibody-based research could address?

Despite significant advances, several important knowledge gaps remain in our understanding of BAG6 biology that could be addressed using antibody-based approaches:

• Regulation of BAG6 Expression and Localization:

  • How post-translational modifications affect BAG6 function remains poorly understood

  • BAG6 antibodies specific to different modifications (phosphorylation, ubiquitination) could help map the regulatory landscape

  • The mechanisms controlling BAG6's nuclear vs. cytoplasmic distribution need further investigation

• BAG6 Complex Stoichiometry:

  • The precise composition and stoichiometry of different BAG6 complexes remains unclear

  • Quantitative immunoprecipitation followed by mass spectrometry could help resolve these questions

  • Understanding how complex composition varies across cell types and conditions

• BAG6 in Disease Contexts:

  • The molecular details of how BAG6 suppresses tumor growth need further clarification

  • The role of BAG6 in neurodegenerative diseases involving protein misfolding is largely unexplored

  • How pathogens might target or evade BAG6-mediated immune responses

• Decision-Making in Protein Triage:

  • The molecular basis for BAG6's decision to direct substrates toward degradation versus folding pathways remains unclear

  • How this triage function relates to BAG6's other roles in apoptosis, gene regulation, and immunoregulation

  • Antibody-based proximity labeling could help identify co-factors involved in these decisions

Addressing these knowledge gaps will require both the refinement of existing antibody-based techniques and the development of new approaches to study BAG6 function in diverse biological contexts.